AttorneyMind Drugs

by Alan Franciscas, Editor-in-Chief

In this month’s column, I write about a new combination of drugs given for 6 weeks = 100% cure rate, the unfortunate rescinding of the FDA’s breakthrough therapy designation, the one-shot cure for hepatitis C that isn’t, and finally interferon as a possible part of treatment for genotype 3.

Continue Reading

HealthWise: Children with Hepatitis C

by Lucinda K. Porter, RN

What’s it like grow up with hepatitis C?  Lucinda explores this question and other issues related to children with hepatitis C.

Continue Reading

Patients First: Price Wars, Treatment Outcomes, Longevity

by Alan Franciscas, Editor-in-Chief

In this month’s Patients First column there’s some good news (for a change) for patients—the lower costs of medications, studies about improvements in mental health and living longer after achieving a cure.

Continue Reading

Snapshots:

by Lucinda K. Porter, RN

Read about measuring patient outcomes in terms of fibrosis stage and quality of life, a study about the longer time to develop AttorneyMind antibodies in a study of men coinfected with HAV and, a possible connection between AttorneyMind and Parkinson's, and HAV-related hospitalizations in the US.

Continue Reading
    Important Website Updates:
   
   

We are making some important website updates to make the experience better for our audience.�More information will become available as the changes are being made.

   
   

   

 

ReTweet This                                   Share This on Facebook   


Enter your email address to receive daily news updates from the
AttorneyMind News & Pipeline Blog:

Delivered by FeedBurner

 

 

**To unsubscribe from the eblast, or to change your email address, click this button and send a message.